Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2015, Article ID 279591, 14 pages
http://dx.doi.org/10.1155/2015/279591
Research Article

Resveratrol, Acetyl-Resveratrol, and Polydatin Exhibit Antigrowth Activity against 3D Cell Aggregates of the SKOV-3 and OVCAR-8 Ovarian Cancer Cell Lines

1Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Melbourne, VIC 3002, Australia
2Department of Obstetrics and Gynaecology, University of Otago, Christchurch, 2 Riccarton Avenue, Christchurch 8011, New Zealand
3School of Biological Sciences, University of Canterbury, Private Bag 4800, Christchurch 8140, New Zealand

Received 3 June 2015; Revised 13 September 2015; Accepted 14 September 2015

Academic Editor: Curt W. Burger

Copyright © 2015 Simon J. Hogg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Bast Jr., B. Hennessy, and G. B. Mills, “The biology of ovarian cancer: new opportunities for translation,” Nature Reviews Cancer, vol. 9, no. 6, pp. 415–428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Lengyel, “Ovarian cancer development and metastasis,” The American Journal of Pathology, vol. 177, no. 3, pp. 1053–1064, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Moghaddam, A. Amini, D. L. Morris, and M. H. Pourgholami, “Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer,” Cancer and Metastasis Reviews, vol. 31, no. 1-2, pp. 143–162, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. J. S. Nielsen, E. Jakobsen, B. Hølund, K. Bertelsen, and A. Jakobsen, “Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer,” International Journal of Gynecological Cancer, vol. 14, no. 6, pp. 1086–1096, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. P. M. Harari, G. W. Allen, and J. A. Bonner, “Biology of interactions: antiepidermal growth factor receptor agents,” Journal of Clinical Oncology, vol. 25, no. 26, pp. 4057–4065, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. K. Kundu and Y.-J. Surh, “Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives,” Cancer Letters, vol. 269, no. 2, pp. 243–261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. G. W. Osmond, E. M. Masko, D. S. Tyler, S. J. Freedland, and S. Pizzo, “In vitro and in vivo evaluation of resveratrol and 3,5-dihydroxy-4′-acetoxy-trans-stilbene in the treatment of human prostate carcinoma and melanoma,” Journal of Surgical Research, vol. 179, no. 1, pp. E141–E148, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. K. S. Stakleff, T. Sloan, D. Blanco, S. Marcanthony, T. Booth, and A. Bishayee, “Resveratrol exerts differential effects in vitro and in vivo against ovarian cancer cells,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 4, pp. 1333–1340, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. J. C. Klink, A. K. Tewari, E. M. Masko et al., “Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways,” Prostate, vol. 73, no. 7, pp. 754–762, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. K. P. L. Bhat and J. M. Pezzuto, “Cancer chemopreventive activity of resveratrol,” Annals of the New York Academy of Sciences, vol. 957, pp. 210–229, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. D. J. Boocock, G. E. S. Faust, K. R. Patel et al., “Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 6, pp. 1246–1252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. X.-L. Tan, G. Marquardt, A. B. Massimi, M. Shi, W. Han, and S. D. Spivack, “High-throughput library screening identifies two novel NQO1 inducers in human lung cells,” American Journal of Respiratory Cell and Molecular Biology, vol. 46, no. 3, pp. 365–371, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Zhang, Q. Li, M. Zhu, Q. Huang, Y. Jia, and K. Bi, “Direct determination of polydatin and its metabolite in rat excrement samples by high-performance liquid chromatography,” Chemical and Pharmaceutical Bulletin, vol. 56, no. 11, pp. 1592–1595, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Liu, S. Zhao, Y. Zhang et al., “Reactive oxygen species-mediated endoplasmic reticulum stress and mitochondrial dysfunction contribute to polydatin-induced apoptosis in human nasopharyngeal carcinoma CNE cells,” Journal of Cellular Biochemistry, vol. 112, no. 12, pp. 3695–3703, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Kimura and H. Okuda, “Effects of naturally occurring stilbene glucosides from medicinal plants and wine, on tumour growth and lung metastasis in lewis lung carcinoma-bearing mice,” Journal of Pharmacy and Pharmacology, vol. 52, no. 10, pp. 1287–1295, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Yao, J.-Y. Wang, L. Liu et al., “Polydatin ameliorates DSS-induced colitis in mice through inhibition of nuclear factor-kappaB activation,” Planta Medica, vol. 77, no. 5, pp. 421–427, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Zhou, R. Yang, Z. Teng et al., “Dose-dependent absorption and metabolism of trans-polydatin in rats,” Journal of Agricultural and Food Chemistry, vol. 57, no. 11, pp. 4572–4579, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Lv, H. Gu, S. Chen, Z. Lou, and L. Shan, “Pharmacokinetic profile of 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside in mice after oral administration of Polygonum multiflorum extract,” Drug Development and Industrial Pharmacy, vol. 38, no. 2, pp. 248–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Domcke, R. Sinha, D. A. Levine, C. Sander, and N. Schultz, “Evaluating cell lines as tumour models by comparison of genomic profiles,” Nature Communications, vol. 4, article 2126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Kobold, S. Hegewisch-Becker, K. Oechsle, K. Jordan, C. Bokemeyer, and D. Atanackovic, “Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?” Oncologist, vol. 14, no. 12, pp. 1242–1251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. K. L. Sodek, M. J. Ringuette, and T. J. Brown, “Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype,” International Journal of Cancer, vol. 124, no. 9, pp. 2060–2070, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Myungjin Lee, P. Mhawech-Fauceglia, N. Lee et al., “A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro,” Laboratory Investigation, vol. 93, no. 5, pp. 528–542, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Hirschhaeuser, T. Leidig, B. Rodday, C. Lindemann, and W. Mueller-Klieser, “Test system for trifunctional antibodies in 3D MCTS culture,” Journal of Biomolecular Screening, vol. 14, no. 8, pp. 980–990, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Nyga, U. Cheema, and M. Loizidou, “3D tumour models: novel in vitro approaches to cancer studies,” Journal of Cell Communication and Signaling, vol. 5, no. 3, pp. 239–248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. A. V. Gudkov and E. A. Komarova, “Pathologies associated with the p53 response,” Cold Spring Harbor Perspectives in Biology, vol. 2, no. 7, Article ID a001180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. C. S. Moreno, L. Matyunina, E. B. Dickerson et al., “Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas,” PLoS ONE, vol. 2, no. 5, article e441, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Pandit and A. L. Gartel, “Proteasome inhibitors induce p53-independent apoptosis in human cancer cells,” The American Journal of Pathology, vol. 178, no. 1, pp. 355–360, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Farrand, S. Byun, J. Y. Kim et al., “Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission,” Journal of Biological Chemistry, vol. 288, no. 33, pp. 23740–23750, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Kueck, A. W. Opipari Jr., K. A. Griffith et al., “Resveratrol inhibits glucose metabolism in human ovarian cancer cells,” Gynecologic Oncology, vol. 107, no. 3, pp. 450–457, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Vergara, P. Simeone, D. Toraldo et al., “Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells,” Molecular BioSystems, vol. 8, no. 4, pp. 1078–1087, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Roncoroni, L. Elli, E. Dolfini et al., “Resveratrol inhibits cell growth in a human cholangiocarcinoma cell line,” Liver International, vol. 28, no. 10, pp. 1426–1436, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Günther, C. Ruhe, M. G. Derikito, G. Böse, H. Sauer, and M. Wartenberg, “Polyphenols prevent cell shedding from mouse mammary cancer spheroids and inhibit cancer cell invasion in confrontation cultures derived from embryonic stem cells,” Cancer Letters, vol. 250, no. 1, pp. 25–35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Dolfini, L. Roncoroni, E. Dogliotti et al., “Resveratrol impairs the formation of MDA-MB-231 multicellular tumor spheroids concomitant with ceramide accumulation,” Cancer Letters, vol. 249, no. 2, pp. 143–147, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. X.-X. Wang, Y.-B. Li, H.-J. Yao et al., “The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells,” Biomaterials, vol. 32, no. 24, pp. 5673–5687, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. K. J. Jeong, K. H. Cho, N. Panupinthu et al., “EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol,” Molecular Oncology, vol. 7, no. 1, pp. 121–129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. A. P. N. Majumdar, S. Banerjee, J. Nautiyal et al., “Curcumin synergizes with resveratrol to inhibit colon cancer,” Nutrition and Cancer, vol. 61, no. 4, pp. 544–553, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. H. K. Choi, J. W. Yang, and K. W. Kang, “Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell,” Cancer Letters, vol. 242, no. 2, pp. 198–206, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Su, Y. Cheng, M. Liu et al., “Comparision of piceid and resveratrol in antioxidation and antiproliferation activities in vitro,” PLoS ONE, vol. 8, no. 1, Article ID e54505, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Nutakul, H. S. Sobers, P. Qiu et al., “Inhibitory effects of resveratrol and pterostilbene on human colon cancer cells: a side by side comparison,” Journal of Agricultural and Food Chemistry, vol. 59, no. 20, pp. 10964–10970, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Marimuthu, K. Kaur, U. Kandalam et al., “Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation,” Journal of Medicinal Food, vol. 14, no. 1-2, pp. 46–52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. M. H. G. Raj, Z. Y. Abd Elmageed, J. Zhou et al., “Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells,” Gynecologic Oncology, vol. 110, no. 3, pp. 432–438, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. A.-K. Marel, G. Lizard, J.-C. Izard, N. Latruffe, and D. Delmas, “Inhibitory effects of trans-resveratrol analogs molecules on the proliferation and the cell cycle progression of human colon tumoral cells,” Molecular Nutrition and Food Research, vol. 52, no. 5, pp. 538–548, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Colin, A. Gimazane, G. Lizard et al., “Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells,” International Journal of Cancer, vol. 124, no. 12, pp. 2780–2788, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. K. R. Patel, V. A. Brown, D. J. L. Jones et al., “Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients,” Cancer Research, vol. 70, no. 19, pp. 7392–7399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Calamini, K. Ratia, M. G. Malkowski et al., “Pleiotropic mechanisms facilitated by resveratrol and its metabolites,” Biochemical Journal, vol. 429, no. 2, pp. 273–282, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. W. A. Spannuth, A. M. Nick, N. B. Jennings et al., “Functional significance of VEGFR-2 on ovarian cancer cells,” International Journal of Cancer, vol. 124, no. 5, pp. 1045–1053, 2009. View at Publisher · View at Google Scholar · View at Scopus